{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:40:04Z","timestamp":1790991604554,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T00:00:00Z","timestamp":1462406400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00520-016-3256-5","type":"journal-article","created":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T06:43:10Z","timestamp":1462430590000},"page":"3633-3650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer\u2014a systematic review"],"prefix":"10.1007","volume":"24","author":[{"given":"Ricardo","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Mazzarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habeeb","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed FK","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,5]]},"reference":[{"issue":"10","key":"3256_CR1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3253","volume":"9","author":"C Dumontet","year":"2010","unstructured":"Dumontet C, Jordan M (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9(10):790\u2013803","journal-title":"Nat Rev Drug Discov"},{"key":"3256_CR2","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/annonc\/mdt194","volume":"24","author":"A Bahl","year":"2013","unstructured":"Bahl A, Oudard S, Tombal B, \u00d6zg\u00fcrog M, Lu HS, et al. (2013) Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 24:2402\u20132408","journal-title":"Ann Oncol"},{"issue":"4","key":"3256_CR3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ctrv.2005.03.007","volume":"31","author":"M Trudeau","year":"2005","unstructured":"Trudeau M, Sinclair SE, Clemons M, et al. (2005) Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review. Cancer Treat Rev 31(4):283\u2013302","journal-title":"Cancer Treat Rev"},{"key":"3256_CR4","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.2010.33.0308","volume":"29","author":"CL Loprinzi","year":"2011","unstructured":"Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472\u20131478","journal-title":"J Clin Oncol"},{"issue":"4","key":"3256_CR5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3747\/co.v17i4.562","volume":"17","author":"S Saibil","year":"2010","unstructured":"Saibil S (2010) Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol 17(4):42\u201347","journal-title":"Curr Oncol"},{"issue":"2","key":"3256_CR6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1634\/theoncologist.2013-0359","volume":"19","author":"K Beusterien","year":"2014","unstructured":"Beusterien K, Grinspan J, Kuchuk I, Mazzarello S, Dent S, Gertler S, et al. (2014) Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. Oncologist 19(2):127\u2013134","journal-title":"Oncologist"},{"issue":"1","key":"3256_CR7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10549-013-2727-3","volume":"142","author":"I Kuchuk","year":"2013","unstructured":"Kuchuk I, Bouganim N, Beusterien K, et al. (2013) Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat 142(1):101\u2013107","journal-title":"Breast Cancer Res Treat"},{"key":"3256_CR8","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","volume":"27","author":"WJ Gradishar","year":"2009","unstructured":"Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, et al. (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27:3611\u20133619","journal-title":"J Clin Oncol"},{"key":"3256_CR9","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","volume":"24","author":"SE Jones","year":"2006","unstructured":"Jones SE, Savin MA, Holmes FA, \u2018shaughnessy JAO, Blum JL, Vukelja S, et al. (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381\u20135387","journal-title":"J Clin Oncol"},{"key":"3256_CR10","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","volume":"24","author":"H Roch\u00e9","year":"2006","unstructured":"Roch\u00e9 H, Fumoleau P, Spielmann M, Canon J-L, Delozier T, Serin D, et al. (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24:5664\u20135671","journal-title":"J Clin Oncol"},{"issue":"22","key":"3256_CR11","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla J-P, Weaver C, et al. (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302\u20132313","journal-title":"N Engl J Med"},{"issue":"5","key":"3256_CR12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3816\/CBC.2002.n.036","volume":"3","author":"RE Smith","year":"2002","unstructured":"Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, et al. (2002) Phase II trial of doxorubicin\/docetaxel\/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58. Clin Breast Cancer 3(5):333\u2013340","journal-title":"Clin Breast Cancer"},{"key":"3256_CR13","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, et al. (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23:3686\u20133696","journal-title":"J Clin Oncol"},{"issue":"17","key":"3256_CR14","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H (2015) Nivolumab versus docetaxel in advanced Nonsquamous non-small cell lung cancer. N Engl J Med 373(17):1627\u20131639","journal-title":"N Engl J Med"},{"issue":"10","key":"3256_CR15","first-page":"947","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. (2009) Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. N engl j med. Chinese Acad Med Sci Shanghai \u2014 all China Maharaj Nakorn Chiang N Engl J Med 361(10):947\u2013957","journal-title":"Chinese Acad Med Sci Shanghai \u2014 all China Maharaj Nakorn Chiang N Engl J Med"},{"issue":"15","key":"3256_CR16","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. (2004) Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502\u20131512","journal-title":"N Engl J Med"},{"issue":"4","key":"3256_CR17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","volume":"15","author":"S Pignata","year":"2014","unstructured":"Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, et al. (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15(4):396\u2013405","journal-title":"Lancet Oncol"},{"issue":"11","key":"3256_CR18","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s00520-015-2731-8","volume":"23","author":"C Jacobs","year":"2015","unstructured":"Jacobs C, Hutton B, Mazzarello S, Smith S, Joy A, Amir E, et al. (2015) Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy\u2014a survey of health care providers and patients. Support Care Cancer 23(11):3269\u20133275","journal-title":"Support Care Cancer"},{"issue":"5","key":"3256_CR19","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/cncr.26410","volume":"118","author":"E Chow","year":"2012","unstructured":"Chow E, Nguyen J, Zhang L, Tseng L-M, Hou M-F, Fairchild A, et al. (2012) International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases. Cancer 118(5):1457\u20131465","journal-title":"Cancer"},{"issue":"4","key":"3256_CR20","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cncr.11578","volume":"98","author":"D Cella","year":"2003","unstructured":"Cella D, Peterman A, Hudgens S, Webster K, Socinski MA (2003) Measuring the side effects of taxane therapy in oncology the functional assessment of cancer therapy\u2013taxane (FACT-taxane). Cancer 98(4):822\u2013831","journal-title":"Cancer"},{"issue":"20","key":"3256_CR21","first-page":"5171","volume":"18","author":"BN Reeves","year":"2012","unstructured":"Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, et al. (2012) Further data supporting that the paclitaxel-associated acute pain syndrome is associated with the development of peripheral neuropathy: NCCTG trial N08C1 1. Hematol Oncol Dayt 18(20):5171\u20135178","journal-title":"Hematol Oncol Dayt"},{"issue":"6","key":"3256_CR22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/PPO.0b013e31815a999b","volume":"13","author":"CL Loprinzi","year":"2007","unstructured":"Loprinzi CL, Maddocks-Christianson K, Wolf SL, Rao RD, Dyck PJB, Mantyh P, Dyck P (2007) The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 13(6):399\u2013403","journal-title":"Cancer J"},{"key":"3256_CR23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1212\/WNL.46.1.108","volume":"46","author":"PZ New","year":"1996","unstructured":"New PZ, Jackson CE, Rinaldi D, et al. (1996) Peripheral neuropathy secondary to docetaxel. Neurology 46:108\u2013111","journal-title":"Neurology"},{"key":"3256_CR24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1212\/WNL.46.1.104","volume":"46","author":"PH Hilkens","year":"1996","unstructured":"Hilkens PH, Verweij J, Stoter G, et al. (1996) Peripheral neurotoxicity induced by docetaxel. Neurology 46:104\u2013108","journal-title":"Neurology"},{"issue":"9","key":"3256_CR25","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2004.99.298","volume":"22","author":"V Nguyen","year":"2004","unstructured":"Nguyen V, Lawrence H (2004) Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol 22(9):1767\u20131769","journal-title":"J Clin Oncol"},{"issue":"4","key":"3256_CR26","first-page":"274","volume":"1","author":"SD Jacobson","year":"2003","unstructured":"Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH, Jatoi AMT (2003) Glutamine does not prevent paclitaxel-associated myalgias and arthralgiasas. J Support Oncol 1(4):274\u2013278","journal-title":"J Support Oncol"},{"issue":"10","key":"3256_CR27","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.1999.17.10.3038","volume":"17","author":"K Gelmon","year":"1999","unstructured":"Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, et al. (1999) Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17(10):3038\u20133047","journal-title":"J Clin Oncol"},{"issue":"12","key":"3256_CR28","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/cncr.28654","volume":"120","author":"AD Leal","year":"2014","unstructured":"Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber C, et al. (2014) NCCTG N08CA (alliance): the use of glutathione for prevention of paclitaxel\/carboplatin induced peripheral neuropathy: a phase III randomized, double-blind placebo-controlled study and for the alliance for clinical trials in oncology. Cancer 120(12):1890\u20131897","journal-title":"Cancer"},{"issue":"9","key":"3256_CR29","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jclinepi.2008.10.012","volume":"62","author":"M Sampson","year":"2009","unstructured":"Sampson M, McGowan J, Cogo E, Grimshaw J, Moher DLC (2009) An evidence-based practice guideline for the peer review of electronic search. J Clin Epidemiol 62(9):944\u2013952","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"3256_CR30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264\u2013269","journal-title":"Ann Intern Med"},{"key":"3256_CR31","doi-asserted-by":"crossref","unstructured":"Higgins Senior Statistician JPT, Altman Director DG, G\u00f8tzsche Director PC, J\u00fcni P. (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343(d5928).","DOI":"10.1136\/bmj.d5928"},{"key":"3256_CR32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/1471-2407-14-515","volume":"14","author":"G Fountzilas","year":"2014","unstructured":"Fountzilas G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki AG, et al. (2014) Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic cooperative oncology group randomized phase III trial. BMC Cancer 14:515","journal-title":"BMC Cancer"},{"key":"3256_CR33","doi-asserted-by":"crossref","unstructured":"Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, Kokko R, Asola R. (2009) Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T)\u2013\u00a0>\u00a05FU\u00a0+\u00a0epirubicin\u00a0+\u00a0cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): Interim analysis of the FinXX-trial. Cancer Res 69:2 Suppl S).","DOI":"10.1158\/0008-5472.SABCS-82"},{"issue":"4","key":"3256_CR34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4103\/0973-1482.92004","volume":"7","author":"WY Kim","year":"2011","unstructured":"Kim WY, Woo U, Seo JH, Son GS, Lee JB, Bae JW (2011) Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases. J Cancer Res Ther 7(4):412\u2013415","journal-title":"J Cancer Res Ther"},{"key":"3256_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/862921","author":"EA Wist","year":"2012","unstructured":"Wist EA, Mjaaland I, L\u00f8kkevik E, Sommer HH (2012) Clinical study weekly paclitaxel plus capecitabine versus docetaxel every 3 weeks plus capecitabine in metastatic breast cancer. J Oncol Hindawi Publishing Corporation. doi: 10.1155\/2012\/862921","journal-title":"J Oncol Hindawi Publishing Corporation"},{"issue":"1","key":"3256_CR36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/jjco\/hyl124","volume":"37","author":"Y-C Lin","year":"2007","unstructured":"Lin Y-C, Chang H-K, Chen J-S, Wang H-M, Yang T-S, Liaw C-C (2007) A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis. Jpn J Clin Oncol 37(1):23\u201329","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"3256_CR37","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/annonc\/mdt543","volume":"25","author":"J Baselga","year":"2014","unstructured":"Baselga J, Manikhas A, Cort\u00e9s J, Llombart A, Roman L, Semiglazov VF, et al. (2014) Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol 25(3):592\u2013598","journal-title":"Ann Oncol"},{"issue":"Suppl.1","key":"3256_CR38","first-page":"S312","volume":"19","author":"M Pasekta","year":"2011","unstructured":"Pasekta M, Giotis A (2011) Characterization of taxane-induced arthralgias and myalgias in breast cancer patients at two ambulatory cancer centres: a prospective observational study. Support Care Cancer 19(Suppl.1):S312","journal-title":"Support Care Cancer"},{"key":"3256_CR39","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/S0959-8049(12)70318-0","volume":"48","author":"SJ Howell","year":"2012","unstructured":"Howell SJ, Armstrong ACAL (2012) Retrospective analysis of the relative efficacy and toxicity of nab-paclitaxel and docetaxel in metastatic breast cancer. Eur J Cancer 48:S115\u2013S116","journal-title":"Eur J Cancer"},{"key":"3256_CR40","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.1016\/S0959-8049(11)71444-7","volume":"47","author":"M Brammer","year":"2011","unstructured":"Brammer M, Lalla D, Guerin A, Yu A, Wu E (2011) Complications associated with chemotherapy in patients with metastatic breast cancer. Eur J Cancer 47:S330","journal-title":"Eur J Cancer"},{"key":"3256_CR41","doi-asserted-by":"crossref","unstructured":"Coudert BP, Pierga J-Y, Mouret-Reynier M-A, Kerrou K, Ferrero J-M, Petit T et al. (2014) An open-label, randomized, multicenter study investigating the addition of bevacizumab to neoadjuvant trastuzumab plus docetaxel in patients with early stage HER2-positive breast cancer stratified according to PET change after one therapy cycle. J Clini Oncol 32(15(Suppl. 1)).","DOI":"10.1200\/jco.2014.32.15_suppl.507"},{"key":"3256_CR42","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/1471-2407-13-583","volume":"13","author":"YW Moon","year":"2013","unstructured":"Moon YW, Lee S, Park B-W, Kim E-K, Kim SI, Koo JS, et al. (2013) S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. BMC Cancer 13:583","journal-title":"BMC Cancer"},{"key":"3256_CR43","first-page":"S173","volume":"48","author":"KT Malgorzata","year":"2012","unstructured":"Malgorzata KT, Soeren C, Ulla BT, Soendergaard S, Nielsen D (2012) Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide+\/\u2212trastuzumab followed by docetaxel in locally advanced breast cancer. Eur J Cancer 48:S173","journal-title":"Eur J Cancer"},{"issue":"2","key":"3256_CR44","first-page":"314","volume":"18","author":"AM Bulent","year":"2013","unstructured":"Bulent AM, Algin E, Inal A, et al. (2013) Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study. J BUON 18(2):314\u2013320","journal-title":"J BUON"},{"issue":"1","key":"3256_CR45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00404-010-1609-8","volume":"284","author":"N Hatam","year":"2011","unstructured":"Hatam N, Ahmadloo N, Ahmad KDA, Daliri A, et al. (2011) Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil). Arch Gynecol Obstet 284(1):215\u2013220","journal-title":"Arch Gynecol Obstet"},{"issue":"7","key":"3256_CR46","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3109\/0284186X.2011.602111","volume":"50","author":"L Eckhoff","year":"2011","unstructured":"Eckhoff L, Nielsen M, Moeller S, Knoop A (2011) TAXTOX \u2013 a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol 50(7):1075\u20131082","journal-title":"Acta Oncol"},{"key":"3256_CR47","doi-asserted-by":"crossref","unstructured":"Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, et al. (2011) Phase III Study of Doxorubicin\/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2\u2013Normal, Node-Positive Breast Cancer: BCIRG-005 Trial. J Clin Oncol 10;29(29):3877\u201384.","DOI":"10.1200\/JCO.2010.28.5437"},{"key":"3256_CR48","doi-asserted-by":"crossref","unstructured":"Miura D, Fujii M, Iwatani T, Takano T, Kawabata H. (2011) Reduction of toxicity by reversing the order of infusion in docetaxel and cyclophosphamide (TC). J Clin Oncol 29(15):Suppl 3.","DOI":"10.1200\/jco.2011.29.15_suppl.2576"},{"key":"3256_CR49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000341384","volume":"7","author":"A Sch\u00f6nherr","year":"2012","unstructured":"Sch\u00f6nherr A, Aivazova-Fuchs V, Annecke K, et al. (2012) Toxicity analysis in the ADEBAR trial: sequential anthracycline-taxane therapy compared with FEC120 for the adjuvant treatment of high-risk breast cancer. Breast Care 7:289\u2013295","journal-title":"Breast Care"},{"key":"3256_CR50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1359-6349(10)70387-6","volume":"8","author":"N Boekel","year":"2010","unstructured":"Boekel N, Schaapveld M, Aleman BMP, et al. (2010) Musculoskeletal pain in the FEC-D regimen is common and frequently severe\u2014experiences in an outer metropolitan oncology unit. Eur J Cancer Suppl 8:163\u2013164","journal-title":"Eur J Cancer Suppl"},{"key":"3256_CR51","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2407-11-140","volume":"11","author":"EJ Kantelhardt","year":"2011","unstructured":"Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, et al. (2011) Prospective evaluation of prognostic factors uPA\/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6\u00a0\u00d7\u00a0FEC versus 3\u00a0\u00d7\u00a0FEC\/3\u00a0\u00d7\u00a0docetaxel. BMC Cancer 11:140","journal-title":"BMC Cancer"},{"issue":"3","key":"3256_CR52","first-page":"216","volume":"8","author":"TK Yau","year":"2010","unstructured":"Yau TK, Sayeed A, Shen ZZ, Kim SB, Ali SM, Villalon AH, et al. (2010) Patterns of care and safety profiles of adjuvant docetaxel-based chemotherapy regimens in a large breast cancer registry study in Asia Pacific. Eur J Cancer Suppl 8(3):216","journal-title":"Eur J Cancer Suppl"},{"key":"3256_CR53","doi-asserted-by":"crossref","unstructured":"Rodriguez-Abreu D, Murias A, Garc\u00eda M et al. (2009) Neoadjuvant biweekly dose-dense chemotherapy with fluouracil, epirubicin, and cyclophosphamide (FEC 90), followed by docetaxel in patients with HER2-neu negative primary breast cancer. J Clin Oncol 27(15s):suppl;abstr 596.","DOI":"10.1200\/jco.2009.27.15_suppl.596"},{"issue":"3","key":"3256_CR54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10549-007-9672-y","volume":"109","author":"KS Lee","year":"2008","unstructured":"Lee KS, Ro J, Nam BH, et al. (2008) A randomized phase-III trial of docetaxel\/capecitabine versus doxorubicin\/cyclophosphamide as primary chemotherapy for patients with stage II\/III breast cancer. Breast Cnacer Res Treat 109(3):481\u2013489","journal-title":"Breast Cnacer Res Treat"},{"key":"3256_CR55","doi-asserted-by":"crossref","unstructured":"Vriens B, Smilde T, Van de Vjiver K. (2011) Sequential versus upfront intensified neoadjuvant chemotherapy in patients with large resectable or locally advanced breast cancer (INTENS), toxicity results from a phase III study of the dutch breast cancer triallists group (BOOG). Cancer Res 71(24):Suppl. 1.","DOI":"10.1158\/0008-5472.SABCS10-P1-11-10"},{"issue":"24","key":"3256_CR56","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1200\/JCO.2010.32.7254","volume":"29","author":"RC Coombes","year":"2011","unstructured":"Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, et al. (2011) Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. J Clin Oncol 29(24):3247\u20133254","journal-title":"J Clin Oncol"},{"key":"3256_CR57","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/COC.0b013e3181bead47","volume":"33","author":"W Jacot","year":"2010","unstructured":"Jacot W, Bibeau F, Gourgou-Bourgade S, Gutowski M, Colombo P-E, Bleuse J-P, et al. (2010) Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer. Am J Clin Oncol 33:544\u2013549","journal-title":"Am J Clin Oncol"},{"key":"3256_CR58","unstructured":"Morimoto M, Nakagawa M, Takechi H, Tadokoro YT (2014) A phase II study with S-1\u00a0+\u00a0docetaxel (N-1 study) for advanced breast cancer. Eur J Cancer 50(S51)"},{"key":"3256_CR59","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1634\/theoncologist.2014-0033","volume":"19","author":"S Swain","year":"2014","unstructured":"Swain S, Baselga J, Miles D, Knott A, Clark E, Ross G, et al. (2014) Safety profile of Pertuzumab with trastuzumab and docetaxel in patients from Asia with human epidermal growth factor receptor 2- positive metastatic breast cancer: results form the phase III trial CLEOPATRA. Oncologist 19:693\u2013701","journal-title":"Oncologist"},{"key":"3256_CR60","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1470-2045(13)70554-0","volume":"15","author":"H Earl","year":"2014","unstructured":"Earl H, Vallier A, Hiller L, Fenwick N, Young J, Iddawela M (2014) Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (neo-tAnGo): an open-label, 2\u00a0\u00d7\u00a02 factorial randomised phase 3 trial. Lancet Oncol 15:201\u2013212","journal-title":"Lancet Oncol"},{"key":"3256_CR61","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/annonc\/mdu124","volume":"25","author":"A Gonzalez-Angulo","year":"2014","unstructured":"Gonzalez-Angulo A, Akcakanat A, Liu S, Green M, Murray J, Chen H (2014) Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol 25:1122\u20131127","journal-title":"Ann Oncol"},{"key":"3256_CR62","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1634\/theoncologist.2013-0075","volume":"18","author":"C Saura","year":"2013","unstructured":"Saura C, Pusztain L (2013) Neoadjuvant doxorubicin\/cyclophosphamide followed by ixabepilone or paclitaxel en early stage breast cancer and evaluation of BIII-tubulin expression as a predictive marker. Oncologist 18:787\u2013794","journal-title":"Oncologist"},{"key":"3256_CR63","doi-asserted-by":"crossref","unstructured":"Cognetti F, Bruzzi P, De PS, De LM, Boni C, Aitini E et al. (2013) Epirubicin and cyclophosphamide followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide followed by T in node-positive early breast cancer patients. Final results of the gruppo Italiano mammella 2 randomized phase III study. Cancer Res 73(24):suppl 1.","DOI":"10.1158\/0008-5472.SABCS13-S5-06"},{"key":"3256_CR64","doi-asserted-by":"crossref","unstructured":"Richardet E, Richardet M, Brombin R, Cortes MN, Molina M, Riso AA et al. (2014) Concurrent chemoradiotherapy (CRT) with paclitaxel in breast cancer stage II-III. J Clin Oncol 32(15):Suppl 1.","DOI":"10.1200\/jco.2014.32.15_suppl.e11522"},{"key":"3256_CR65","unstructured":"Eduardo arnoldo Richardet, Perelli Laura, Martin Eduardo Richardet, Nicolas Castagneris, Matias Nicolas Cortes MM. (2012) Concomitant chemoradiotherapy in women with stage II-III breast cancer. J Clin Oncol 30:suppl;abstr e11501."},{"issue":"1","key":"3256_CR66","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-010-1136-0","volume":"125","author":"J Haba-Rodr\u00edguez De La","year":"2011","unstructured":"De La Haba-Rodr\u00edguez J, Rodr\u00edguez-Lescure A, Ruiz A, et al. (2011) Regional and seasonal influence in patient\u2019s toxicity to adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat 125(1):273\u2013278","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3256_CR67","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/0019-509X.75836","volume":"48","author":"DS Palappallil","year":"2011","unstructured":"Palappallil DS, Nair BL, Jayakumar KL, et al. (2011) Comparative study of the toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycin-cyclophosphamide followed by paclitaxel in carcinoma breast. Indian J Cancer 48(1):68\u201373","journal-title":"Indian J Cancer"},{"issue":"6","key":"3256_CR68","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1634\/theoncologist.2012-0129","volume":"18","author":"FJ Esteva","year":"2013","unstructured":"Esteva FJ, Franco SX, Hagan MK, et al. (2013) An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. Oncologist 18(6):661\u2013666","journal-title":"Oncologist"},{"key":"3256_CR69","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s11136-011-9999-z","volume":"21","author":"C Moinpour","year":"2012","unstructured":"Moinpour C, Donaldson G, Liepa A, Albain K (2012) Evaluating health-related quality of life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monothe. Qual Life Res 21:765\u2013775","journal-title":"Qual Life Res"},{"key":"3256_CR70","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s10549-013-2589-8","volume":"139","author":"H-J L\u00fcck","year":"2013","unstructured":"L\u00fcck H-J, Andreas Du Bois B, Sibylle Loibl B, Iris Schrader B, Jens Huober B, Volker Heilmann B, et al. (2013) Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO breast cancer study group. Breast Cancer Res Treat 139:779\u2013787","journal-title":"Breast Cancer Res Treat"},{"key":"3256_CR71","doi-asserted-by":"crossref","unstructured":"Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, et al. (2010) A randomized phase II trial comparing 3-h versus 96-h infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer 116 (4):814\u2013821.","DOI":"10.1002\/cncr.24870"},{"issue":"5","key":"3256_CR72","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cncr.22885","volume":"110","author":"HJ Burstein","year":"2007","unstructured":"Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Kelly Marcom P, et al. (2007) Trastuzumab plus Vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and Vinorelbine or taxane study. Cancer 110(5):965\u2013972","journal-title":"Cancer"},{"issue":"9","key":"3256_CR73","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.bjc.6600261","volume":"86","author":"D Talbot","year":"2002","unstructured":"Talbot D, Moiseyenko V, Van BS, O \u2018reilly S, Conejo EA, Ackland S, et al. (2002) Randomised, phase II trial comparing oral capecitabine (Xeloda 1) with paclitaxel in patients with metastatic\/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86(9):1367\u20131372","journal-title":"Br J Cancer"},{"key":"3256_CR74","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1200\/JCO.2001.19.6.1707","volume":"19","author":"J Jassem","year":"2001","unstructured":"Jassem J, Pienkowski T (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707\u20131715","journal-title":"J Clin Oncol"},{"key":"3256_CR75","doi-asserted-by":"crossref","unstructured":"Saracchini S, Foltran L, Bassini A, Sulfaro S, Lorenzon M, Micheli E et al. (2014) Neoadjuvant chemotherapy with nonpegylated liposome-encapsulated doxorubicin (NPLD) plus cyclophosphamide followed by trastuzumab plus nabpaclitaxel for HER2-positive breast cancer (BC). J Clin Oncol 32(15):suppl 1","DOI":"10.1200\/jco.2014.32.15_suppl.648"},{"key":"3256_CR76","unstructured":"Tsugawa K, Kawamoto H, Kojima Y, Tsuchiya K, Shimo A, Hayami R et al. (2014) Feasibility study of weekly nanoparticle albumin-bound (nab)-paclitaxel (150 mg\/m2) followed by 5FU, epirubicin, plus cyclophosphamide (FEC) as neoadjuvant chemotherapy for HER2-negative breast cancer. Eur J Cancer 50(S51)."},{"key":"3256_CR77","doi-asserted-by":"crossref","unstructured":"Seki H, Asanuma F, Yamada Y, Hirata Y, Kaneda M, Suzuki K et al. (2014) Safety of weekly administration of nanoparticle albumin-bound paclitaxel in patients with breast cancer. Eur J Cancer 50(e.41).","DOI":"10.1016\/j.ejca.2014.03.160"},{"issue":"2","key":"3256_CR78","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clbc.2011.10.004","volume":"12","author":"LS Schwartzberg","year":"2012","unstructured":"Schwartzberg LS, Arena FP, Mintzer DM, Epperson AL, Walker MS (2012) Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer. Clinical Breast Cancer 12(2):87\u201393","journal-title":"Clinical Breast Cancer"},{"key":"3256_CR79","doi-asserted-by":"crossref","unstructured":"Seidman AD, Conlin AK, Bach A, Moynahan ME, Lake D, Forero A, et al. (2013) Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer. Clinical Breast Cancer 13(4):239\u201346.e1.","DOI":"10.1016\/j.clbc.2013.02.008"},{"issue":"supp 2","key":"3256_CR80","first-page":"s67","volume":"19","author":"M Pasekta","year":"2011","unstructured":"Pasekta M, De Angelis C, Van Draanen J, Stacey E, Dent R (2011) Characterization of taxane-induced arthralgias and myalgias in breast cancer patients at two ambulatory cancer centres: a Prospecrtive observational study. Support Care Cancer 19(supp 2):s67\u2013370","journal-title":"Support Care Cancer"},{"key":"3256_CR81","doi-asserted-by":"crossref","unstructured":"Fernandes R, Mazzarello S, Majeed H, Smith S, Shorr R, Hutton B, et al. (2016) Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy\u2014a systematic review. Support Care Cancer 24(4):1583\u20131594","DOI":"10.1007\/s00520-015-2941-0"},{"issue":"suppl 7","key":"3256_CR82","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1359-6349(10)72259-X","volume":"8","author":"S Damaraju","year":"2010","unstructured":"Damaraju S, Ghosh S, Tuszynski J, Greiner R, et al. (2010) CYP3A5*3 (rs776746) is associated with docetaxel-specific toxicities during adjuvant breast cancer chemotherapy. Eur J Cancer 8(suppl 7):175","journal-title":"Eur J Cancer"},{"issue":"suppl(24)","key":"3256_CR83","first-page":"258s","volume":"70","author":"S Damaraju","year":"2010","unstructured":"Damaraju S, Sehrawat BS, Ghosh S, Pituskin E, et al. (2010) Germline Copy Number Polymorphisms Associated with Toxicity from Adjuvant Docetaxel. Cancer Res 70(suppl(24)):258s","journal-title":"Cancer Res"},{"key":"3256_CR84","unstructured":"clinicaltrials.gov A Multi-Centre Study to Investigate the Natural History of Taxane Acute Pain Syndrome (TAPS) in Patients Receiving Taxane Chemotherapy for Breast or Prostate Cancer. NCT02362087 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02362087"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3256-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3256-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3256-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T23:58:21Z","timestamp":1655683101000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3256-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,5]]},"references-count":84,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["3256"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3256-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,5]]}}}